Trifluoroacetic acid → (S)-N-((3S,4S)-1-((7-methoxy-2-oxo-2H-chromen-4-yl)methyl)-4-methyl-5-(2-(methylsulfonyl)acetyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino) propanamide 2,2,2-trifluoroacetate
Reaction equation
[CH3:1][O:2][C:3]1[CH:12]=[C:11]2[C:6]([C:7]([CH2:14][N:15]3[C:21](=[O:22])[C@@H:20]([NH:23][C:24](=[O:36])[C@@H:25]([N:27](C)[C:28](=O)OC(C)(C)C)[CH3:26])[C@H:19]([CH3:37])[N:18]([C:38](=[O:44])[CH2:39][S:40]([CH3:43])(=[O:42])=[O:41])[C:17]4[CH:45]=[CH:46][CH:47]=[CH:48][C:16]3=4)=[CH:8][C:9](=[O:13])[O:10]2)=[CH:5][CH:4]=1.[C:49]([OH:55])([C:51]([F:54])([F:53])[F:52])=[O:50]>C(Cl)Cl>[F:52][C:51]([F:54])([F:53])[C:49]([OH:55])=[O:50].[CH3:1][O:2][C:3]1[CH:12]=[C:11]2[C:6]([C:7]([CH2:14][N:15]3[C:21](=[O:22])[C@@H:20]([NH:23][C:24](=[O:36])[C@@H:25]([NH:27][CH3:28])[CH3:26])[C@H:19]([CH3:37])[N:18]([C:38](=[O:44])[CH2:39][S:40]([CH3:43])(=[O:42])=[O:41])[C:17]4[CH:45]=[CH:46][CH:47]=[CH:48][C:16]3=4)=[CH:8][C:9](=[O:13])[O:10]2)=[CH:5][CH:4]=1Participants
4
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
To a rt solution of tert-butyl(S)-1-((3S,4S)-1-((7-methoxy-2-oxo-2H-chromen-4-yl)methyl)-4-methyl-5-(2-(methylsulfonyl)acetyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-ylamino)-1-oxopropan-2-yl(methyl)carbamate (42.7 mg, 62.4 μmol) in CH2Cl2 (249 μl) was added TFA (62.4 μl). The reaction was stirred at rt for 1.5 h, then concentrated, taken up in H2O, and lyophilized to provide (S)-N-((3S,4S)-1-((7-methoxy-2-oxo-2H-chromen-4-yl)methyl)-4-methyl-5-(2-(methylsulfonyl)acetyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino) propanamide 2,2,2-trifluoroacetate (41.2 mg, 95%) as a white solid. MS m/z 585 (MH)+.
Workup
- concentrationconcentrated
Sources & evidence
- ORD record
- ord-e78d84314750404bb2cd160a09fa1983
- Source dataset
- uspto-grants-2016_08
- Patent number
- US09422331B2
Reaction notes
Loading…